The overall objective of this proposal is to study the pharmacogenetics - pharmacokinetics correlation (PG-PK) of six commonly used anti-cancer drugs (docetaxel, imatinib, pemetrexed, tamoxifen, 6-mercaptopurine and 5-fluorouracil) and its implications for cancer outcome and toxicity, with an aim to personalize therapy. Apart from exploring the PK-PG association of these drugs, the project also aims at elucidating the frequency of single nucleotide polymorphisms (SNPs) in core ADME genes in 300 cancer patients in the Indian population. A long term objective of this research is to develop an India specific SNP array of the ADME genes that can be used across indications to predict toxic or sub-optimal exposure of drugs and preempt dose modifications. It is envisaged that such an array would be made available for public use at very competitive price so that it can be widely used across the country. This personalized approach to treatment will reduce the cost while increasing the effectiveness of healthcare delivery.